Intralesional immunotherapy for non-genital warts: A systematic review and meta-analysis

Background: Intralesional immunotherapy has been reported to be effective for warts and to show good safety profiles, but this has not yet been systematically studied. Aims: To determine the efficacy and safety of intralesional immunotherapy for treating non-genital warts. Methods: We comprehensively searched the MEDLINE, Embase, Web of Science and Cochrane Library databases from the times of their inception to January 3, 2020. The primary outcome was the rate of complete response of all lesions. The distant complete response rate of warts located in an anatomically different body part and the recurrence rate were also analyzed. Results: A total of 54 prospective studies was ultimately included. The immunotherapeutic agents used were Mycobacterium w vaccine, measles, mumps and rubella vaccine, purified protein derivative, Candida antigen, interferon, bacillus Calmette-Guérin vaccine and others. The pooled rate of complete response among all patients with non-genital warts treated using intralesional immunotherapy was 60.6% (95% confidence interval 54.8–66.5%). The pooled recurrence rate was 2.0% (95% confidence interval, 1.1–2.9%). All reported adverse events were mild and transient. Limitations: The heterogeneity among studies Conclusion: Intralesional immunotherapy is suggested for use in patients with multiple warts, given its promising results, good safety profile and low recurrence rate.

Acquired Lymphangioma Circumscriptum of Vulva Mimicking Genital Wart: The Utility of Dermoscopy in Differential Diagnosis / 대한피부과학회지

No abstract available.

Tratamiento de las verrugas genitales: una actualización / Genital wart treatment: an update

La infección por el Virus del Papiloma Humano es una afección altamente prevalente a nivel mundial y una de sus consecuencias es la verruga genital externa o condiloma genital. El tratamiento de estas lesiones ha sido tradicionalmente difícil, debido a la alta recurrencia de las lesiones. Se revisan los aspectos más novedosos del tratamiento de las verrugas genitales. Las sinecatequinas y una nueva formulación de Imiquimod al 3,75% resaltan como las terapéuticas más novedosas, mientras que la terapia fotodinámica carece de evidencia científica adecuada como para recomendar su uso rutinario. Las vacunas profilácticas y terapéuticas parecen poseer un gran potencial pero aún se encuentran en fases iniciales de investigación. Es deseable estudios con un mayor número de pacientes y un seguimiento más prolongado, que permita una comparación directa de la efectividad entre las diferentes técnicas terapéuticas a corto y largo plazo.

Human Papillomavirus infection is a highly prevalent condition worldwide whose frequent consequence is the external genital wart or genital condyloma. The treatment for this condition has been traditionally difficult due to the recurrence of the lesions. The most innovative aspects of the treatment of genital wart, are reviewed. The sinecatechins and a new formulation of Imiquimod 3.75% stand out as the most innovative therapeutic, while photodynamic therapy lacks adequate scientific evidence to recommend its routine use. The prophylactic and therapeutic vaccines seem to have great potential but are still in early stages of research. Studies should be conducted with larger patient samples and longer follow-ups to allow comparison of the effectiveness among the different therapeutic techniques in the short and long term.

Prevalência de condiloma acuminado no município de Campo Grande - Mato Grosso do Sul, no período de 2006 a 2009 / Prevalence of genital warts in Campo Grande - Mato Grosso do Sul in the period 2006 to 2009

O presente estudo visa estimar a prevalência de lesões condilomatosas causadas pela infecção por papilomavírus humano (HPV), no município de CampoGrande - Mato Grosso do Sul, no período de 2006 a 2009. Foi um estudo transversal de prevalência, realizado através de levantamento de dados fornecidos pelo Sistema Nacional de Agravos Notificáveis (SINAN), do município de Campo Grande, no período de 2006 a 2009, após solicitação protocolada. Foram notificados 961 casos de lesões condilomatosas, havendo maior prevalência no sexo masculino; em 2008 houve o maior número de notificações. Em 2009 ocorreu o maior número de casos em pacientes menores de 10 anos. A grande maioria foi diagnosticada com menos de 3 meses de evolução. Foi observada elevação crescente da infecção ao longo do período estudado, com ênfase para os casos novos em crianças com menos de 10 anos, o que infere aumento da incidência em pacientes gestantes, repercutindo em um maior índice de transmissão vertical. Também é notório o salto observado no número de casos na transição entre a pré-adolescência e a adolescência, inferindo o início da atividade sexual precoce destas pacientes.

This study aims to estimate the prevalence of condyloma lesions caused by infection with human papillomavirus (HPV), in Campo Grande - Mato Grossodo Sul in the period 2006 to 2009. It was a cross-sectional study of prevalence conducted through a survey of data provided by the National Notifiable Diseases (SINAN) of Campo Grande in the period 2006 to 2009, after request filed. Were reported 961 cases of condyloma lesions, with prevalence amongmales; in 2008 was higher numbers of notifications. In 2009 occurred the greatest number of cases in patients younger than 10 years. The vast majority werediagnosed under 3 months. Was observed growing areas of infection throughout the period studied, with emphasis on new cases in children younger than 10years, which implies increased incidence in pregnant patients resulting in higher rate of vertical transmission, and is also notorious jump observed in the number of cases in the transition from pre-adolescence and adolescence, inferring the onset of early sexual activity of these patients.

Condiloma acuminado - resposta terapêutica com imiquimode e cirurgia / Genital wart - therapeutic response with immiquimod and surgery

O condiloma acuminado é uma das manifestações do papilomavírus humano (HPV) na área genital. Relata-se o caso de uma paciente do sexo feminino, 27 anos com extensa lesão condilomatosa na região vulvar. O tratamento foi realizado com exérese cirúrgica das lesões maiores, seguido da aplicação de imiquimode nas lesões menores e recidivas, com resolução clínica completa em 8 semanas. Foram abordadas as diferentes formas de tratamento com enfoque na terapêutica com imiquimode.

Condylomata acuminata is one of the genital manifestations of the Human papillomavírus (HPV) infection in the genital area. This is a case report of a 27 years-old female patient with extensive genital warts in the vulvar. The treatment was performed with surgical ressection of the biggest warts and local application of immiquimod in the others lesions and relapses. The complete clinical resolution was observed in 8 weeks. We will review the different forms of treatment emphasing immiquimod treatment.

Papilomavirose humana em genital, parte I / Genital human papilomavirosis, part I

Nas últimas décadas, algumas doenças têm adquirido proporções epidêmicas mundialmente. Dentre essas pandemias, pode-se destacar a infecção genital pelo papilomavírus humano (HPV). A infecção pelo HPV geralmente é assintomática e, na maioria dos casos, é transitória, já queo sistema imunológico pode ser capaz de combater o processo infeccioso, resolvendo-o ou tornando-o inativo. Vários tipos do HPV são causadoresde lesões genitais, manifestando-se, por exemplo, como condiloma acuminado. Algumas lesões genitais podem associar-se à infecçãopersistente e ao desenvolvimento de neoplasias intraepiteliais e até de câncer, ao longo de anos. Há muito tempo procura-se uma terapia que sejaconsiderada definitiva para as doenças causadas pelo HPV. Atualmente, as opções vão da ablação da lesão até a sua destruição com agentes químicos ou físicos. Pela frequência com que a infecção genital pelo HPV se manifesta na população, suas múltiplas aparências clínicas e o avançoem novas opções de abordagem para essas doenças são focos constantes de pesquisas. Diversas modalidades de tratamento já estão disponíveis para as lesões genitais pelo HPV, desde as citodestrutivas até a excisão cirúrgica. A utilização de produtos autoaplicáveis e em domicílio pode ter bons resultados para o paciente. A disponibilidade de vacinas contra HPV para a população pode ser o início de nova era na prevenção primária da infecção por HPV. Todavia, os milhões de casos clínicos de infecção por HPV, sobretudo os de condiloma acuminado, serão responsáveis por muitos anos de trabalho árduo para tratar as pessoas já acometidas. Este artigo, parte I, propõe-se a fazer uma ampla revisão sobre os principais aspectos da etiopatogenia, da clínica, do diagnóstico, do tratamento e da profilaxia de lesões genitais por HPV.

In recent decades, some diseases have reached epidemic proportions worldwide. Among these pandemics, genital infection by Human Papillomavirus (HPV) can be highlighted. HPV infection is usually asymptomatic and, in most cases, is transient, since the immune system may be able to fi ght the infectious process by either solving it or inactivating it. Several types of HPV cause genital lesions, and can be manifested as, for example, a condyloma acuminata. Some genital lesions can be associated to persistent infection and development of intraepithelial neoplasia and even cancer in time. For many years, there has been a demand for a defi nite therapy to treat HPV. Nowadays, the options range from the ablation of the lesion to its destruction with chemical or physical agents. Based on the frequency with which genital HPV infection manifests itself in the population, its many clinical aspects and the advances of new options to approach these diseases, it has become a continuous research focus. Several types of treatment are available forgenital HPV lesions, ranging from the cytodestructive treatments to those carried out by surgical excision. The use of self and domestic applicableproducts can present good results for the patient. The availability of HPV vaccines for the population may be the beginning of a new era in the primary prevention of HPV infection. However, the millions of cases of HPV infection, especially the condyloma acuminatum will be responsible for many years of hard work treating those already infected. This article, Part I, attempts to carry out a comprehensive review on the main pathogenic, clinical, diagnostic, treatment and prophylactic aspects of HPV genital lesions.

Recommendation guideline of Korean Society of Gynecologic Oncology and Colposcopy for quadrivalent human papillomavirus vaccine / 부인종양

Genital HPV infection is the most common sexually transmitted infection, but the majority of infections are self-limited. However, persistent infection with high-risk types can cause cervical cancer in women, which is the most common female genital cancer in Korea. In addition, HPV infection is the cause of genital warts and is associated with other anogenital cancers. The HPV vaccine is composed of the HPV L1 protein, the major capsid protein of HPV. Expression of the L1 protein in yeast using recombinant DNA technology produces noninfectious virus-like particles (VLP) that resemble HPV virions. The quadrivalent HPV vaccine is a mixture of four HPV type-specific VLPs prepared from the L1 proteins of HPV 6, 11, 16, and 18 combined with an aluminum adjuvant. Clinical trials indicate that the vaccine has high efficacy in preventing persistent HPV infection, cervical cancer precursor lesions, vaginal and vulvar cancer precursor lesions, and genital warts caused by HPV types 6, 11, 16, or 18 among females who have not already been infected with the respective HPV type. The recommended age for primary vaccination of Korean females is 15-17 years, considering sexual debut and duration of protection of the vaccine. Vaccine can be administered as young as age 9 years. Catch-up vaccination is recommended for females aged 18-26 years who have not been previously vaccinated. Vaccination is not a substitute for routine cervical cancer screening, and vaccinated females should have cervical cancer screening as recommended.